BridgeBio Pharma, Inc. BBIO
74.96 USD -2.93 (-3.76%)
Nov 5, 2026, 1:19 PM EST
74.77 Day range 78.58
60.55 52-week range 93.42
- YTD
- -2.00%
- 1 year
- +19.63%
News
globenewswire.com BridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026 PALO ALTO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on…
benzinga.com Canaccord Genuity Maintains Buy on BridgeBio Pharma, Raises Price Target to $108 Canaccord Genuity analyst Whitney Ijem maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $106 to $108.
fool.com Should You Invest $1,000 in BridgeBio Pharma Right Now? BridgeBio saw revenue climb by 193% year over year in the third quarter. The company's lead therapy is a heart drug, Attruby.
benzinga.com TD Cowen Maintains Buy on BridgeBio Pharma, Lowers Price Target to $100 TD Cowen analyst Tyler Van Buren maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and lowers the price target from $110 to $100.
benzinga.com Morgan Stanley Maintains Overweight on BridgeBio Pharma, Raises Price Target to $88 Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $87 to $88.
seekingalpha.com BridgeBio Pharma, Inc. (BBIO) Q3 2026 Earnings Call Transcript BridgeBio Pharma, Inc. (BBIO) Q3 2026 Earnings Call Transcript
marketbeat.com What BridgeBio Pharma (BBIO) Said on Its Q3 Earnings Call BridgeBio Pharma NASDAQ: BBIO reported third-quarter revenue growth driven by sales of ATTR cardiomyopathy treatment Attruby and a one-time milestone tied to European partner Bayer's…
zacks.com BridgeBio Pharma (BBIO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for BridgeBio Pharma (BBIO) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall…
zacks.com BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.6. This compares to a loss of $0.95 per share a year ago.
benzinga.com BridgeBio Pharma Q3 2026 Earnings Call Transcript BridgeBio Pharma (NASDAQ:BBIO) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.
benzinga.com BridgeBio Pharma Q3 2026 Earnings Call Transcript BridgeBio Pharma (NASDAQ:BBIO) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
globenewswire.com BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates - $353.2 million in total third quarter revenues, primarily comprised of $253.2 million of U.S. Attruby net product revenue (up approximately $31 million sequentially and $145 million year over…
globenewswire.com BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET PALO ALTO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic…
benzinga.com Morgan Stanley Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $87 Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and lowers the price target from $97 to $87.
zacks.com 4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now BBIO, NTLA, BIIB and VKTX offer investors potential upside from promising drug pipelines and upcoming FDA decisions and pivotal study results.- benzinga.com Citigroup Maintains Neutral on BridgeBio Pharma, Lowers Price Target to $91 Citigroup analyst Eric Joseph maintains BridgeBio Pharma (NASDAQ:BBIO) with a Neutral and lowers the price target from $94 to $91.
benzinga.com Piper Sandler Maintains Overweight on BridgeBio Pharma, Raises Price Target to $120 Piper Sandler analyst Biren Amin maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $115 to $120.
globenewswire.com BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PALO ALTO, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic…
defenseworld.net Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM) Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE: TSM). In a filing disclosed on October 12th, the…
seekingalpha.com BridgeBio: Maintaining 'Strong Buy' Additional Encaleret Data ADH1 And Three Expected FDA Reviews BridgeBio Pharma maintains a "Strong Buy" rating, driven by robust revenue growth and multiple late-stage pipeline catalysts. The company delivered Q2 2026 net revenues of $243.7M, up from the prior…- benzinga.com Reported Sunday, BridgeBio’s Encaleret Raises Bone Turnover, With 100% Of Phase 3 CALIBRATE Participants Reporting Improvement In At Least One ADH1 Symptom Versus 46% On Standard Of Care - Encaleret administration increased bone turnover, based on its action to recover endogenous PTH secretion in patients with ADH1- 100% of participants who received encaleret reported improvements in…
benzinga.com Reported Sunday, BridgeBio Presents Acoramidis Data At HFSA 2026 Showing 18% Lower Composite Risk Versus Tafamidis In Real-World Study Of 2,684 ATTR-CM Patients And Mortality Rising After Cardiovascular Hospitalizations - In an independent, propensity score-matched analysis of 2,684 individuals living with ATTR-CM from Epic COSMOS, the largest U.S. electronic health record database, acoramidis was associated with a…
globenewswire.com Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records - In an independent, propensity score-matched analysis of 2,684 individuals living with ATTR-CM from Epic COSMOS, the largest U. S. electronic health record database, acoramidis was associated with a…
zacks.com FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing BBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therapy for achondroplasia.- benzinga.com Barclays Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $156 Barclays analyst Eliana Merle maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and lowers the price target from $157 to $156.
globenewswire.com BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on…
globenewswire.com BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026 PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on…
benzinga.com BridgeBio Pharma Receives FDA Acceptance For Filing Its New Drug Application With Priority Review For Oral Infigratinib To Treat Achondroplasia BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today…
globenewswire.com BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia - Accepted for Priority Review with a PDUFA target action date of February 4, 2027; being granted Priority Review by the FDA underscores the significant unmet need for an oral targeted therapeutic…
globenewswire.com BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day - October 6 YouTube premiere featuring Sway Calloway, Howard “H” White and leading medical and cultural voices anchors community education nationwide- benzinga.com Bridgebio Presents New Exploratory Cardiac Data From 12-Month Interim Analysis Of FORTIFY, Phase 3 Clinical Trial Of Oral BBP-418 In Individuals With Limb-Girdle Muscular Dystrophy Type 2I/R9, At 31st Annual Congress Of The World Muscle Society In Hiroshima - In exploratory analyses at Month 12, among individuals with LGMD2I/R9 (FKRP-related) with elevated HS troponin I at baseline, 100% treated with BBP-418 returned to the normal range by Month 12…
globenewswire.com BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels - In exploratory analyses at Month 12, among individuals with LGMD2I/R9 (FKRP-related) with elevated HS troponin I at baseline, 100% treated with BBP-418 returned to the normal range by Month 12…- benzinga.com HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $120 price target.
benzinga.com BridgeBio Dwarfism Data Shows Broad Health Benefits Beyond Height Gain BridgeBio Pharma shares 52-week data on oral infigratinib for achondroplasia, showing improvements in sleep apnea, otitis media, and BMI.
benzinga.com BridgeBio's Oral Infigratinib Shows Reduced Sleep Apnea And Ear Infection Rates Beyond Growth Benefits In Phase 3 PROPEL 3 Trial At 52 Weeks - Treatment with oral infigratinib for 52 weeks in PROPEL 3 resulted in favorable trends against placebo in clinically meaningful exploratory endpoints including sleep apnea and otitis media…- benzinga.com HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $120 price target.
- benzinga.com Mizuho Maintains Outperform on BridgeBio Pharma, Raises Price Target to $110 Mizuho analyst Salim Syed maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and raises the price target from $96 to $110.
benzinga.com Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President Trump secures drug pricing deals with nine pharma companies as Kennedy reveals intense pressure from the President to deliver.- benzinga.com Trump Administration Reaches New Drug Pricing Agreement With Nine Pharma Firms https://www.whitehouse.gov/fact-sheets/2026/08/fact-sheet-president-donald-j-trump-announces-deal-with-nine-additional-pharmaceutical-manufacturers-to-lower-drug-prices-for-americans/
- benzinga.com Reported Earlier, BridgeBio Reports New Data Suggesting Attruby Could Help Reverse Some Heart Damage BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, presented new
benzinga.com BridgeBio Pharma Doses First Patient In ASCEND-ATTR Trial To Evaluate Effects Of Acoramidis To Enhance Cardiac Structure, Function, And Amyloid Burden In Individuals With Transthyretin Amyloid Cardiomyopathy BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today- benzinga.com BridgeBio Pharma To Present Two Oral Presentations, Three Posters On New Acoramidis Data In Individuals With Transthyretin Amyloid Cardiomyopathy At European Society Of Cardiology Congress 2026 BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that two oral presentations and
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com BridgeBio Pharma Launches Secondary Public Offering Of 5M Shares Of Common Stock By Selling Stockholder KKR Genetic Disorder L.P BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today the launch of a…
- benzinga.com Truist Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $107 Truist Securities analyst Danielle Brill maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $102 to $107.
- benzinga.com Canaccord Genuity Maintains Buy on BridgeBio Pharma, Raises Price Target to $106 Canaccord Genuity analyst Whitney Ijem maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $104 to $106.
- benzinga.com JP Morgan Maintains Overweight on BridgeBio Pharma, Raises Price Target to $111 JP Morgan analyst Anupam Rama maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $100 to $111.
- benzinga.com B of A Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $104 B of A Securities analyst Geoff Meacham maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $101 to $104.
- benzinga.com TD Cowen Maintains Buy on BridgeBio Pharma, Raises Price Target to $110 TD Cowen analyst Tyler Van Buren maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $95 to $110.
- benzinga.com Morgan Stanley Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $97 Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and lowers the price target from $98 to $97.